Abstract: The present invention provides compounds having Formula I and their use for the treatment of cancer.

Abstract: Compounds having the formula (I), and pharmaceutically-acceptable salts, hydrates and prodrugs thereof, are useful as anti-inflammatory agents, in which R1, R2, and R3 are hydrogen, halogen, alkyl, or perfluoroalkyl; R4 is an optionally substituted alkyl or cycloalkyl group; X is a linker; A is an aryl, heteroaryl, heterocycle, cycloalkyl, or is absent; and R7 is a substituent on A as defined in the specification.

Abstract: Inhibitors of the cytosolic phospholypase A2 enzymes are provided which are of use in controlling a wide variety of inflammatory diseases. The inhibitors of the present invention have the general formula wherein X, Z, X1, R1, R2, Ra, Rb, R3, R4 and Y are as defined in the specification.

Abstract: An LED lighting device is provided which is capable of being connected to a network and being controlled by a host computer also connected to the network. The lighting device has several lifespan expanding features such as including several extra LEDs such that as the LEDs of the lighting device degrade over time more LEDs can be turned on thus allowing a constant luminosity to be maintained.

Abstract: Compounds having the formula (I), 1

Abstract: An LED lighting device is provided which is capable of being connected to a network and being controlled by a host computer also connected to the network. The lighting device has several lifespan expanding features such as including several extra LEDs such that as the LEDs of the lighting device degrade over time more LEDs can be turned on thus allowing a constant luminosity to be maintained.

Abstract: Inhibitors of the cytosolic phospholypase A2 enzymes are provided which are of use in controlling a wide variety of inflammatory diseases.

Abstract: Certain novel substituted (5,6)-dihydroanthracenyl compounds of the general formula ##STR1## wherein A, n, p, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7 and R.sub.8 are as defined in the specification exhibit retinoid-like properties and are particularly useful in the prevention of post-surgical adhesions.

Abstract: There is provided a novel series of malonate derivatives of glycolipid compounds of the formula ##STR1## wherein R is an acyl residue of a fatty acid:R.sup.1 is --(CH.dbd.CH).sub.m --(CH.sub.2).sub.n --CH.sub.3 ;R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 each are independently hydrogen, unsubstituted or substituted (lower)alkanoyl, arylalkyl or arylcarbonyl wherein said substituent is selected from the group consisting of halogen, C.sub.1-4 alkyl, trifluoromethyl, hydroxy and C.sub.1-4 alkoxy provided that one of R.sup.2, R.sup.3, R.sup.4 and R.sup.6 substituents is --(CH.sub.2).sub.p --CH(CO.sub.2 R.sup.7).sub.2 ;m is an integer of 0 or 1;n is an integer of from 5 to 14 inclusive;p is an integer of from 2 to 6 inclusive; andR.sup.

Abstract: There is provided a novel series of O-carboxymethylated .alpha.- and .beta.-glycolipid compounds of the formula ##STR1## wherein R is an acyl residue of a fatty acid;R.sup.1 is --(CH.dbd.CH).sub.m --(CH.sub.2).sub.n --CH.sub.3 ;R.sup.2, R.sup.3, R.sup.4 R.sup.5 and R.sup.6 each are independently hydrogen, unsubstituted or substituted alkanoyl, arylalkyl or arylcarbonyl wherein said substituent is selected from halogen, C.sub.1-4 alkyl, trifluoromethyl, hydroxy and C.sub.1-4 alkoxy;R.sup.3, R.sup.4 and R.sup.6 each are independently --CH.sub.2 COOR.sup.7, provided at least two of the R.sup.3, R.sup.4 and R.sup.6 substituents are --CH.sub.2 COOR.sub.7 ;m is an integer of 0 or 1;n is an integer of from 5 to 14, inclusive; andR.sup.

Abstract: Compounds of the formula ##STR1## wherein A is an unsubstituted or hydroxy-substituted straight or branched C.sub.1-10 alkylene group or a straight or branched C.sub.1-10 alkylene group having an intervening heteroatom selected from oxygen, sulfur and nitrogen;R.sup.2 is hydroxy, halogen, C.sub.1-4 alkoxy, nitrile, azido, a quaternary ammonio group, --NR.sup.5 R.sup.6, ##STR2## azetidinyl, or a 5- or 6-membered heterocyclic group selected from heteroaromatic and heteroalicyclic joined through a carbon atom thereof;or a non-toxic pharmaceutically acceptable salt thereof, are novel antimicrobial agents which are useful in the treatment of infectious disease in humans and other animals. Novel intermediates and processes for their preparation are also disclosed.

Abstract: There is provided novel sulfated .alpha.-glycolipid compounds of the formula ##STR1## wherein R is an acyl residue of a fatty acid;R.sup.1 is --(CH.dbd.CH).sub.m --(CH.sub.2).sub.n --CH.sub.3 ;R.sup.2, R.sup.3, R.sup.4and R.sup.6 are independently at least two --SO.sub.3 H;R.sup.2, R.sup.3, R.sup.4R.sup.5 and R.sup.6 each are independently hydrogen, unsubstituted or substituted alkanoyl, arylalkyl or arylcarbonyl wherein said substituent is selected from halogen, C.sub.1-4 alkyl, trifluoromethyl, hydroxy and C.sub.1-4 alkoxy;m is an integer of 0 or 1;n is an integer of from 5 to 14, inclusive;or a non-toxic pharmaceutically acceptable salt, solvate or hydrate thereof which are inhibitors of selectin-mediated cellular adhesion and are useful in the treatment or prevention of inflammatory diseases and other pathological conditions in mammals.

Abstract: There is provided novel sulfated p-glycolipid compounds of the formula ##STR1## wherein R is an acyl residue of a fatty acid;R.sup.1 is --(CH.dbd.CH).sub.m --(CH.sub.2).sub.n --CH.sub.3 ;R.sup.2, R.sup.3, R.sup.4 and R.sup.6 each are independently --SO.sub.3 H, hydrogen, unsubstituted or substituted alkanoyl, arylalkyl or arylcarbonyl wherein said substituent is selected from the group consisting of halogen, C.sub.1-4 alkyl, trifluoromethyl, hydroxy and C.sub.1-4 alkoxy; or R.sub.4 and R.sub.6, taken together are isopropylidene; provided at least two of R.sup.2, R.sup.3, R.sup.4 and R.sup.6 are --SO.sub.3 H;R.sup.5 is hydrogen, unsubstituted or substituted alkanoyl, arylalkyl or arylcarbonyl wherein said substituent is selected from the group consisting of halogen, C.sub.1-4 alkyl, trifluoromethyl, hydroxy and C.sub.

Abstract: A color and intensity modulation system has an output to be connected to a color light projector and an input to receive a hue control signal and an intensity control signal including at least one modulation frequency component F. The system comprises a color scaling device, receiving in use the hue signal, the color scaling device producing a plurality of color component signals, the plurality of color component signals being supplied as the output to the color light projector, and an intensity control device, receiving in use the intensity control signal, the intensity control device comprising a low frequency oscillator whose output is an intensity modulation signal for varying an intensity of the plurality of color component signals between a preset minimum and a preset maximum value, the oscillator having a frequency responsive to the at least one modulation frequency component F of the intensity control signal, the plurality of color component signals to control in use the projector.

Abstract: Disclosed herein is a novel high .beta.-yield producing novel intermediates of the formula ##STR1## where R.sup.4 is ##STR2## useful in the synthesis of 1-.beta.-alkyl carbapenems.

Abstract: Disclosed herein is a novel process using novel silyl enol ether intermediates of the formula ##STR1## to generate novel azetidione thiolester intermediates of the formula ##STR2## which can be used to form 1-.beta.-alkyl carbapenem antibiotics. It has now been discovered that if the R.sup.4 group is selected from a small group of moieties having the formula: ##STR3## an increased .beta.-yield of up to approximately 100% can be obtained.

Abstract: Novel carbapenem antibiotics are prepared in which the 2-substituent has the formula ##STR1## wherein n is 0, 1, 2, 3, m, is 1 or 2, and R is C.sub.1 -C.sub.6 alkyl, allyl, propargyl, carboxymethyl, cyanomethyl or aralkyl wherein the aryl moiety is phenyl or heteroaryl and the alkyl moiety is C.sub.1 -C.sub.6 alkyl, said heterocyclic ring containing the sulfonium group being optionally substituted at a ring carbon atom or atoms by one or two C.sub.1 -C.sub.6 alkyl groups.

Abstract: A novel stereocontrolled process is disclosed for converting 6-aminopenicillanic acid to an optically active azetidinone of the formula ##STR1## wherein R" is a hydroxy-protecting group by use of a 6,6-dihaloanhydropenicillin or 6,6-bis(phenylselenyl)anhydropenicillin intermediate.

Abstract: A novel stereocontrolled process is disclosed for converting 6-aminopenicillanic acid to an optically active azetidinone of the formula ##STR1## wherein R" is a hydroxy-protecting group by use of a 6,6-dihaloanhydropenicillin or 6,6-bis(phenylselenyl)anhydropenicillin intermediate.

Abstract: This invention relates to 2-substituted and 2,6-disubstituted penem compounds of the formula ##STR1## wherein Y is hydrogen, halo or certain organic radicals and X represents certain hetero-interrupted substituted alkyl radicals. Also included in the invention are pharmaceutically acceptable salts of the above compounds and derivatives of the above compounds in which the carboxyl group at the 3-position is protected as by an easily removable ester protecting group. The compounds of the present invention are potent antibacterial agents or are of use as intermediates in the preparation of such agents.